Available in Argentina, United States
This is a two-part (1 year double-blind inclisiran versus placebo / 1 year open-label
inclisiran) multicenter study designed to evaluate safety, tolerability, and efficacy of
inclisiran in children (aged 6 to <12 years) with heterozygous familial
hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDL-C) on
stable standard of care background lipid-lowering therapy.
51Patients around the world